首页> 美国卫生研究院文献>Journal of Lipid Research >Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
【2h】

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts

机译:内化的PCSK9从抵抗PCSK9的SV-589成纤维细胞中的回收LDL受体解离

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Secreted PCSK9 binds to cell surface LDL receptor (LDLR) and directs the receptor for lysosomal degradation. PCSK9 is potent at inducing LDLR degradation in cultured liver-derived cells, but it is considerably less active in immortalized fibroblasts. We examined PCSK9 trafficking in SV-589 human skin fibroblasts incubated with purified recombinant wild-type PCSK9 or gain-of-function mutant PCSK9-D374Y with increased LDLR binding affinity. Despite LDLR-dependent PCSK9 uptake, cell surface LDLR levels in SV-589 fibroblasts were only modestly reduced by wild-type PCSK9, even at high nonphysiological concentrations (20 µg/ml). Internalized 125I-labeled wild-type PCSK9 underwent lysosomal degradation at high levels, indicating its dissociation from recycling LDLRs. PCSK9-D374Y (2 µg/ml) reduced cell surface LDLRs by approximately 50%, but this effect was still blunted compared with HepG2 hepatoma cells. Radioiodinated PCSK9-D374Y was degraded less efficiently in SV-589 fibroblasts, and Alexa488-labeled PCSK9-D374Y trafficked to both lysosomes and endocytic recycling compartments. Endocytic recycling assays showed that more than 50% of internalized PCSK9-D374Y recycled to the cell surface compared with less than 10% for wild-type PCSK9. These data support that wild-type PCSK9 readily dissociates from the LDLR within early endosomes of SV-589 fibroblasts, contributing to PCSK9-resistance. Although a large proportion of gain-of-function PCSK9-D374Y remains bound to LDLR in these cells, degradative activity is still diminished.
机译:分泌的PCSK9与细胞表面LDL受体(LDLR)结合并指导该受体进行溶酶体降解。 PCSK9在诱导培养的肝源细胞中有效诱导LDLR降解,但在永生化成纤维细胞中的活性明显较低。我们检查了与纯化的重组野生型PCSK9或功能获得的突变型PCSK9-D374Y(具有增加的LDLR结合亲和力)一起孵育的SV-589人皮肤成纤维细胞中的PCSK9转运。尽管摄取了依赖LDLR的PCSK9,但即使在高非生理浓度(20 µg / ml)下,野生型PCSK9也只能适度降低SV-589成纤维细胞中细胞表面的LDLR水平。内化的 125 I标记的野生型PCSK9经历了高水平的溶酶体降解,表明其与回收的LDLR分离。 PCSK9-D374Y(2 µg / ml)将细胞表面的LDLR降低了约50%,但与HepG2肝癌细胞相比,这种作用仍然减弱。放射性碘标记的PCSK9-D374Y在SV-589成纤维细胞中降解的效率较低,Alexa488标记的PCSK9-D374Y既向溶酶体又向内吞再循环室贩运。内源性回收测定表明,超过50%的内化PCSK9-D374Y回收到细胞表面,而野生型PCSK9则不到10%。这些数据支持野生型PCSK9容易在SV-589成纤维细胞的早期内体中与LDLR分离,从而有助于PCSK9的抵抗。尽管在这些细胞中大部分功能获得性PCSK9-D374Y仍与LDLR结合,但降解活性仍然降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号